文献速递白血病

复发急性髓系白血病的基因组特征揭示新的潜在治疗靶点

Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
PubMed 文献 · Blood Adv · 2021-01-01

该研究对48例成人及25例儿童急性髓系白血病(AML)患者的纵向诊断、复发和/或原发耐药标本进行全基因组和全外显子组测序,发现复发时频发获得ARID1A和CSF1R突变,均为潜在可干预的治疗靶点;成人与儿童复发AML突变谱存在差异,成人复发时频见MGA和H3F3A p.Lys28Met突变,而UBTF内部串联重复仅见于儿童;复发时还发现IKZF1、KANSL1和NIPBL频发突变,这些基因在初诊de novo AML中未见报道或频率极低,提示其参与疾病进展和/或治疗耐药。

要点

  • 复发时频发获得ARID1A和CSF1R突变,为潜在可干预靶点。
  • 成人复发AML频见MGA和H3F3A p.Lys28Met突变,儿童仅见UBTF内部串联重复。
  • 复发时新发现IKZF1、KANSL1和NIPBL频发突变,初诊时罕见或未见。

核心结论

  • 复发AML存在频发获得性突变,包括ARID1A和CSF1R等潜在治疗靶点。
  • 成人与儿童复发AML突变谱存在差异,提示年龄特异性的疾病进展机制。
  • IKZF1、KANSL1和NIPBL突变在复发时频发,初诊de novo AML中罕见或未见,可能参与疾病进展和/或治疗耐药。

研究设计与样本

  • 对48例成人及25例儿童AML患者的纵向诊断、复发和/或原发耐药标本进行全基因组和全外显子组测序分析。

主要发现

  • 复发时频发获得ARID1A和CSF1R突变。
  • 成人复发AML频见MGA和H3F3A p.Lys28Met突变,儿童复发AML仅见UBTF内部串联重复。
  • 复发时频发IKZF1、KANSL1和NIPBL突变,这些基因在初诊de novo AML中未见报道或频率极低。

临床怎么用

  • 对复发AML进行基因组测序可识别ARID1A、CSF1R等潜在可干预靶点,为个体化治疗提供依据。
  • 成人与儿童复发AML突变谱差异提示年龄特异性的治疗策略选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is the leading cause of death of adult and pediatric patients with acute myeloid leukemia (AML). Numerous studies have helped to elucidate the complex mutational landscape at diagnosis of AML, leading to improved risk stratification and new therapeutic options. However, multi-whole-genome studies of adult and pediatric AML at relapse are necessary for further advances. To this end, we performed whole-genome and whole-exome sequencing analyses of longitudinal diagnosis, relapse, and/or primary resistant specimens from 48 adult and 25 pediatric patients with AML. We identified mutations recurrently gained at relapse in ARID1A and CSF1R, both of which represent potentially actionable therapeutic alternatives. Further, we report specific differences in the mutational spectrum between adult vs pediatric relapsed AML, with MGA and H3F3A p.Lys28Met mutations recurrently found at relapse in adults, whereas internal tandem duplications in UBTF were identified solely in children. Finally, our study revealed recurrent mutations in IKZF1, KANSL1, and NIPBL at relapse. All of the mentioned genes have either never been reported at diagnosis in de novo AML or have been reported at low frequency, suggesting important roles for these alterations predominantly in disease progression and/or resistance to therapy. Our findings shed further light on the complexity of relapsed AML and identified previously unappreciated alterations that may lead to improved outcomes through personalized medicine.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stratmann S, Yones SA, Mayrhofer M, et al. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. Blood Adv. 2021. PMID: 33560403. doi:10.1182/bloodadvances.2020003709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。